Novocure Ltd NVCR

Novocure Ltd is a biopharmaceutical oncology-focused company engaged in the development and commercialisation of a novel cancer treatment that targets solid tumours, known as Tumour Treating Fields or TTFields. This treatment focuses on the disruption of cancer cell division through the use of alternating electric fields applied at specific frequencies. The firm has its corporate headquarters in Saint Helier in Jersey, with offices in the US, Switzerland, Tokyo, and Haifa. The firm was founded in 2000.

Novocure Ltd has brought two FDA approved products to market that use TTFields to treat both newly diagnosed and recurrent glioblastoma. Products in the pipeline are being developed with the aim of treating patients with brain metastasis, non-small cell lung cancer, ovarian cancer, mesothelioma, liver cancer, gastric cancer, and traditionally hard-to-treat pancreatic cancer.

TTFields therapy is delivered through a portable medical device, and the treatment is designed to enable patients to receive continuous cancer treatment with minimal disruption to their daily lives and activities. The firm is listed on the NASDAQ, where it trades under the stock ticker NVCR.

You can add this company to your watchlist here on eToro to get regular news and instant updates on changes to the NVCR price chart.